{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Bronchogenic&page=82",
    "query": {
      "condition": "Carcinoma, Bronchogenic",
      "page": 82
    },
    "page_size": 10
  },
  "pagination": {
    "page": 82,
    "page_size": 10,
    "total_count": 3597,
    "total_pages": 360,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Bronchogenic&page=83&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Bronchogenic&page=81&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-01T01:42:19.092Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00086333",
      "title": "FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "SGN-15, Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2004-07",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2011-10-24",
      "last_synced_at": "2026-11-01T01:42:19.092Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Baltimore, Maryland • Portland, Oregon",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00086333"
    },
    {
      "nct_id": "NCT00707252",
      "title": "Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Polyphenon E",
          "type": "DRUG"
        },
        {
          "name": "Tarceva",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Louisiana State University Health Sciences Center Shreveport",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2008-01",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2015-04-21",
      "last_synced_at": "2026-11-01T01:42:19.092Z",
      "location_count": 1,
      "location_summary": "Shreveport, Louisiana",
      "locations": [
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00707252"
    },
    {
      "nct_id": "NCT05859217",
      "title": "A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer",
        "NSCLC Stage IV",
        "Metastatic NSCLC - Non-Small Cell Lung Cancer",
        "Advanced NSCLC"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jun Zhang, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2024-12",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2024-05-08",
      "last_synced_at": "2026-11-01T01:42:19.092Z",
      "location_count": 4,
      "location_summary": "Kansas City, Kansas • Overland Park, Kansas • Kansas City, Missouri + 1 more",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Lee's Summit",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05859217"
    },
    {
      "nct_id": "NCT03261947",
      "title": "A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Pancreatic Cancer",
        "Colorectal Cancer",
        "Esophageal Neoplasms",
        "Carcinoma, Non-small-cell Lung"
      ],
      "interventions": [
        {
          "name": "TAK-931",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2017-10-25",
      "completion_date": "2020-08-24",
      "has_results": true,
      "last_update_posted_date": "2021-09-20",
      "last_synced_at": "2026-11-01T01:42:19.092Z",
      "location_count": 8,
      "location_summary": "Denver, Colorado • Sarasota, Florida • Minneapolis, Minnesota + 5 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03261947"
    },
    {
      "nct_id": "NCT01928576",
      "title": "Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Epigenetic Therapy"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Entinostat",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "CC-486 300",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 143,
      "start_date": "2013-11-06",
      "completion_date": "2023-04-04",
      "has_results": true,
      "last_update_posted_date": "2024-05-03",
      "last_synced_at": "2026-11-01T01:42:19.092Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Baltimore, Maryland + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01928576"
    },
    {
      "nct_id": "NCT00787852",
      "title": "A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47",
          "type": "DRUG"
        },
        {
          "name": "Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2009-03",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2014-07-30",
      "last_synced_at": "2026-11-01T01:42:19.092Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00787852"
    },
    {
      "nct_id": "NCT05451849",
      "title": "A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Mesothelioma",
        "Mesotheliomas Pleural",
        "Mesothelioma, Malignant",
        "Mesothelioma Peritoneum",
        "Ovarian Cancer",
        "Ovarian Serous Adenocarcinoma",
        "Pancreatic Cancer",
        "Pancreatic Adenocarcinoma",
        "Colorectal Cancer",
        "Triple Negative Breast Cancer",
        "TNBC - Triple-Negative Breast Cancer",
        "Ovarian Adenocarcinoma",
        "Pancreatic Neoplasms",
        "Colorectal Neoplasms",
        "Ovarian Neoplasms",
        "Cholangiocarcinoma",
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "TC-510",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "TCR2 Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2022-06-21",
      "completion_date": "2025-08-30",
      "has_results": true,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-11-01T01:42:19.092Z",
      "location_count": 7,
      "location_summary": "San Franciso, California • Miami, Florida • Bethesda, Maryland + 4 more",
      "locations": [
        {
          "city": "San Franciso",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05451849"
    },
    {
      "nct_id": "NCT02695290",
      "title": "Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung",
        "ErbB Receptors"
      ],
      "interventions": [
        {
          "name": "Afatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2016-03-17",
      "completion_date": "2016-08-26",
      "has_results": true,
      "last_update_posted_date": "2017-09-18",
      "last_synced_at": "2026-11-01T01:42:19.092Z",
      "location_count": 1,
      "location_summary": "Fountain Valley, California",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02695290"
    },
    {
      "nct_id": "NCT00651508",
      "title": "Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "KOS-1584",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2008-04",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2016-05-17",
      "last_synced_at": "2026-11-01T01:42:19.092Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00651508"
    },
    {
      "nct_id": "NCT00080340",
      "title": "Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non Small Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "TLK286 (Telcyta) HCl for Injection",
          "type": "DRUG"
        },
        {
          "name": "gefitinib (Iressa)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Telik",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 520,
      "start_date": null,
      "completion_date": "2005-05",
      "has_results": false,
      "last_update_posted_date": "2008-01-15",
      "last_synced_at": "2026-11-01T01:42:19.092Z",
      "location_count": 270,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Benton, Arkansas + 174 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00080340"
    }
  ]
}